Elaine Chen, PhD

Scientist, Translational Biology & Discovery at Rondo Therapeutics

Speaker

Elaine Chen earned her B.Sc. from Texas A&M University in 2017 and her Ph.D. from Vanderbilt University in 2022. During her PhD, she focused on understanding the human antibody repertoire’s response to infectious diseases, including Influenza, Ebola, and SARS-CoV-2, leveraging bioinformatics and high-throughput functional antibody characterization techniques for a comprehensive understanding of public clonotypes and B-cell evolution. After completing her Ph.D., Elaine joined Rondo Therapeutics as an early team member, where she played a pivotal role in establishing the company’s antibody discovery pipeline. She now leads target antibody discovery through lead selection and oversees translational biology efforts to advance Rondo’s lead assets toward IND readiness.